In this issue of the European Journal of Internal Medicine, Torres-Iglesias and colleagues present an observational study of 23 patients with hereditary hemorrhagic telangiectasia (HHT) and atrial fibrillation who underwent left atrial appendage closure (LAAC) for stroke prevention [1]. Therapeutic anticoagulation is normally indicated for 30–45 days following LAAC, with transition to dual antiplatelet therapy for 6 months followed by indefinite single-agent antiplatelet therapy [2]. However, in their report, the authors describe use of a simplified antithrombotic therapy regimen consisting of single-agent low-dose antiplatelet therapy (aspirin 100 mg or clopidogrel 75 mg daily) for 3 months in this cohort of patients with HHT undergoing the procedure.
